In this perspective, Talhouk et al. [34] developed a more pragmatic testing method for molecular assessment of EC, known as Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE), intending to create a clinically applicable molecular-based classification system for EC [35], based on MMR protein search (MLH1, MSH2, MSH6, PMS2) by immunohistochemistry, POLE mutational analysis, and p53 immunohistochemistry as a surrogate for ‘copy-number’ status instead of genomic methodology [34]. Here, POLE is linked to endometrial cancer.